This study just adds to a growing body of evidence that questions the purported benefits of Pradaxa.
New York, New York (PRWEB) March 28, 2013
As Pradaxa lawsuits continue to mount, Bernstein Liebhard LLP notes that a new study presented last week at the American College of Cardiology has raised questions about the effectiveness of new-generation blood thinners, including Pradaxa. The study, which aggregated data from three large randomized trials, found that collectively, Pradaxa, Eliquis and Xarelto were no better at preventing strokes in patients with nonvalvular atrial fibrillation than decades-old warfarin. The new agents did appear, however, to significantly reduce the risk of hemorrhagic stroke compared with the older drug, the study found.*
“We have heard from numerous individuals who suffered serious, life-threatening episodes of Pradaxa bleeding, a frightening Pradaxa side effect for which there is no readily-available antidote. This study just adds to a growing body of evidence that questions the purported benefits of Pradaxa,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Pradaxa lawsuit evaluations to victims of alleged Pradaxa bleeding.
Pradaxa Side Effects
Pradaxa was approved for sale by the U.S. Food & Drug Administration (FDA) in October 2012 to prevent strokes in people with a heart-rhythm disorder known as atrial fibrillation. According to a recent Bloomberg.com report, regulators in several countries have issued Pradaxa side effect alerts since the drug was first brought to market. The report also noted that the FDA received reports of 542 deaths and 3,781 side-effect incidents tied to the drug in 2011.**
According to the Bloomberg report, one of the major issues with Pradaxa is the fact that there exists no readily available antidote for internal bleeding that can sometimes occur in patients treated with the drug. Dialysis can be used to remove Pradaxa from the blood stream. However, a study published last May in the journal, Neurology, found this treatment is risky and may not be administered in enough time to stop this potentially deadly Pradaxa side effect.*** According to a recent QuarterWatch Report from the Institute for Safe Medicine Practices (ISMP), an analysis of hemorrhage cases reported to the FDA during the second quarter of 2012 found that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding.****
Court records indicate that more than 358 plaintiffs have filed Pradaxa lawsuits in a multidistrict litigation now underway in U.S. District Court, Southern District of Illinois. Among other things, the lawsuits alleged the Boehringer Ingelheim sold the blood thinner despite knowing it could cause fatal bleeding in some patients, and failed to adequately warn that there was no readily-available antidote for Pradaxa bleeding. According to court documents, the first trials in the Pradaxa litigation are scheduled to begin in September 2014. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
Victims of serious Pradaxa bleeding may be eligible to collect compensation for their medical bills, lost wages, pain and suffering and more. To learn more please visit the firm’s website, or call 1-877-779-1414 to speak with an attorney today.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com